Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Participants With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Completed · Phase 2 · Has a placebo group

Conditions studied: Multiple Sclerosis

In brief

The primary objective of the study is to evaluate the efficacy of BIIB033 in participants with active relapsing multiple sclerosis (MS) when used concurrently with Avonex. Secondary objectives of this study in this study population are to assess the safety, tolerability, and population pharmacokinetics of BIIB033 when used concurrently with Avonex.

Key facts

Study ID
NCT01864148
Run by
Biogen
People needed
419
Starts
2013-08-01
Expected to finish
2016-03-01
Last updated by the study team
2017-05-03

Who can join

Age: 18 and older, up to 58. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.